Evidence map›Paper›PMID 38066526›Full record

ArticleParasites & vectors2023

Therapeutic effect of Echinococcus granulosus cyst fluid on bacterial sepsis in mice.

Shuying Wang, Donghui Jiang, Feifei Huang, Yayun Qian, Meitao Qi, Huihui Li, Xiaoli Wang, Zhi Wang, Kaigui Wang, Yin Wang and 5 more

Open access · goldAbstract read
In one paragraph

Article in Parasites & vectors, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Frontiers in cellular and infection microbiology · 2025
    Article
  5. Frontiers in microbiology · 2025
    Article
  6. Review
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 7 institutions in 2 countries.

Shuying Wang *First Affiliated Hospital of Bengbu Medical College, Bengbu, 233000, China.
Donghui Jiang *Department of Critical Care Medicine, Affiliated Hospital of Jiangnan University, Wuxi, 214122, China.
Feifei HuangFirst Affiliated Hospital of Bengbu Medical College, Bengbu, 233000, China.
Yayun QianFirst Affiliated Hospital of Bengbu Medical College, Bengbu, 233000, China.
Meitao QiDepartment of Pediatrics, Anqing First People's Hospital of Anhui Medical University, Anqing, 246000, China.
Huihui LiAnhui Key Laboratory of Infection and Immunity of Bengbu Medical College, Bengbu, 233000, China.
Xiaoli WangAnhui Key Laboratory of Infection and Immunity of Bengbu Medical College, Bengbu, 233000, China.
Zhi WangAnhui Key Laboratory of Infection and Immunity of Bengbu Medical College, Bengbu, 233000, China.
Kaigui WangAnhui Key Laboratory of Infection and Immunity of Bengbu Medical College, Bengbu, 233000, China.
Yin WangDepartment of Critical Care Medicine, Affiliated Hospital of Jiangnan University, Wuxi, 214122, China.
Pengfei DuDepartment of Critical Care Medicine, Affiliated Hospital of Jiangnan University, Wuxi, 214122, China.
Bin ZhanNational School of Tropical Medicine, Baylor College of Medicine, Houston, TX, 77030, USA.
Rui ZhouFirst Affiliated Hospital of Bengbu Medical College, Bengbu, 233000, China.
Liang ChuAnhui Key Laboratory of Infection and Immunity of Bengbu Medical College, Bengbu, 233000, China. chew8151@163.com.
Xiaodi YangAnhui Key Laboratory of Infection and Immunity of Bengbu Medical College, Bengbu, 233000, China. yxd_qf@163.com.
Bengbu Medical College · CNFirst Affiliated Hospital of Bengbu Medical College · CNJiangnan University · CNAnhui Medical University · CNAnqing City Hospital · CNBaylor College of Medicine · USWuxi Fourth People's Hospital · CN

Funding

512 Talents Development Project of Bengbu Medical College by51201205512 Talents Development Project of Bengbu Medical College by51201306the Key Projects of Scientific Research of Anhui Provincial Health and Wellness Commission AHWJ2021a005the Major Projects of Wuxi Municipal Health and Wellness Commission Z202114the Support Program for Excellent Talents in Higher Educational Institutions in Anhui Province gxyq2021188
6 · The paper itself

Abstract

backgroundThe primary pathophysiological process of sepsis is to stimulate a massive release of inflammatory mediators to trigger systemic inflammatory response syndrome (SIRS), the major cause of multi-organ dysfunction and death. Like other helminths, Echinococcus granulosus induces host immunomodulation. We sought to determine whether E. granulosus cyst fluid (EgCF) displays a therapeutic effect on sepsis-induced inflammation and tissue damage in a mouse model.

methodsThe anti-inflammatory effects of EgCF were determined by in vitro culture with bone marrow-derived macrophages (BMDMs) and in vivo treatment of BALB/C mice with cecal ligation and puncture (CLP)-induced sepsis. The macrophage phenotypes were determined by flow cytometry, and the levels of cytokines in cell supernatants or in sera of mice were measured (ELISA). The therapeutic effect of EgCF on sepsis was evaluated by observing the survival rates of mice for 72 h after CLP, and the pathological injury to the liver, kidney, and lung was measured under a microscope. The expression of TLR-2/MyD88 in tissues was measured by western blot to determine whether TLR-2/MyD88 is involved in the sepsis-induced inflammatory signaling pathway.

resultsIn vitro culture with BMDMs showed that EgCF promoted macrophage polarization to M2 type and inhibited lipopolysaccharide (LPS)-induced M1 macrophages. EgCF treatment provided significant therapeutic effects on CLP-induced sepsis in mice, with increased survival rates and alleviation of tissue injury. The EgCF conferred therapeutic efficacy was associated with upregulated anti-inflammatory cytokines (IL-10 and TGF-β) and reduced pro-inflammatory cytokines (TNF-α and INF-γ). Treatment with EgCF induced Arg-1-expressed M2, and inhibited iNOS-expressed M1 macrophages. The expression of TLR-2 and MyD88 in EgCF-treated mice was reduced.

conclusionsThe results demonstrated that EgCF confers a therapeutic effect on sepsis by inhibiting the production of pro-inflammatory cytokines and inducing regulatory cytokines. The anti-inflammatory effect of EgCF is carried out possibly through inducing macrophage polarization from pro-inflammatory M1 to regulatory M2 phenotype to reduce excessive inflammation of sepsis and subsequent multi-organ damage. The role of EgCF in regulating macrophage polarization may be achieved by inhibiting the TLR2/MyD88 signaling pathway.

Indexed as

Echinococcus granulosusSepsisAnimalsAnti-Inflammatory AgentsCyst FluidCytokinesInflammationLipopolysaccharidesMiceMice, Inbred BALB CMyeloid Differentiation Factor 88Toll-Like Receptor 2Anti-Inflammatory AgentsCytokinesLipopolysaccharidesMyeloid Differentiation Factor 88Toll-Like Receptor 2Cyst fluidEchinococcus granulosusImmunomodulationMacrophageSepsis

Identifiers

PMID38066526
PMCPMC10709918
OpenAlexW4389485166

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.